BACKGROUND AND PURPOSE: Melanin-concentrating hormone (MCH) is an orexigen, and while rodents express one MCH receptor (MCH1 receptor), humans, non-human primates and dogs express two MCH receptors (MCH1 and MCH2 ). MCH1 receptor antagonists have been developed for the treatment of obesity and lower body weight in rodents. However, the mechanisms for the body weight loss and whether MCH1 receptor antagonism can lower body weight in species expressing both MCH receptors are not fully understood. EXPERIMENTAL APPROACH: A novel recently identified potent MCH1 receptor antagonist, AZD1979, was studied in wild type and Mchr1 knockout (KO) mice and by using pair-feeding and indirect calorimetry in diet-induced obese (DIO) mice. The effect of AZD1979 on body weight was also studied in beagle dogs. KEY RESULTS: AZD1979 bound to MCH1 receptors in the CNS and dose-dependently reduced body weight in DIO mice leading to improved homeostasis model assessment-index of insulin sensitivity. AZD1979 did not affect food intake or body weight in Mchr1 KO mice demonstrating specificity for the MCH1 receptor mechanism. In DIO mice, initial AZD1979-mediated body weight loss was driven by decreased food intake, but an additional component of preserved energy expenditure was apparent in pair-feeding and indirect calorimetry studies. AZD1979 also dose-dependently reduced body weight in dogs. CONCLUSION AND IMPLICATIONS: AZD1979 is a novel potent MCH1 receptor antagonist that affects both food intake and energy expenditure. That AZD1979 also lowers body weight in a species expressing both MCH receptors holds promise for the use of MCH1 receptor antagonists for the treatment of human obesity.
BACKGROUND AND PURPOSE:Melanin-concentrating hormone (MCH) is an orexigen, and while rodents express one MCH receptor (MCH1 receptor), humans, non-human primates and dogs express two MCH receptors (MCH1 and MCH2 ). MCH1 receptor antagonists have been developed for the treatment of obesity and lower body weight in rodents. However, the mechanisms for the body weight loss and whether MCH1 receptor antagonism can lower body weight in species expressing both MCH receptors are not fully understood. EXPERIMENTAL APPROACH: A novel recently identified potent MCH1 receptor antagonist, AZD1979, was studied in wild type and Mchr1 knockout (KO) mice and by using pair-feeding and indirect calorimetry in diet-induced obese (DIO) mice. The effect of AZD1979 on body weight was also studied in beagle dogs. KEY RESULTS:AZD1979 bound to MCH1 receptors in the CNS and dose-dependently reduced body weight in DIO mice leading to improved homeostasis model assessment-index of insulin sensitivity. AZD1979 did not affect food intake or body weight in Mchr1 KO mice demonstrating specificity for the MCH1 receptor mechanism. In DIO mice, initial AZD1979-mediated body weight loss was driven by decreased food intake, but an additional component of preserved energy expenditure was apparent in pair-feeding and indirect calorimetry studies. AZD1979 also dose-dependently reduced body weight in dogs. CONCLUSION AND IMPLICATIONS: AZD1979 is a novel potent MCH1 receptor antagonist that affects both food intake and energy expenditure. That AZD1979 also lowers body weight in a species expressing both MCH receptors holds promise for the use of MCH1 receptor antagonists for the treatment of humanobesity.
Authors: P M Lembo; E Grazzini; J Cao; D A Hubatsch; M Pelletier; C Hoffert; S St-Onge; C Pou; J Labrecque; T Groblewski; D O'Donnell; K Payza; S Ahmad; P Walker Journal: Nat Cell Biol Date: 1999-09 Impact factor: 28.824
Authors: D S Ludwig; N A Tritos; J W Mastaitis; R Kulkarni; E Kokkotou; J Elmquist; B Lowell; J S Flier; E Maratos-Flier Journal: J Clin Invest Date: 2001-02 Impact factor: 14.808
Authors: J Chambers; R S Ames; D Bergsma; A Muir; L R Fitzgerald; G Hervieu; G M Dytko; J J Foley; J Martin; W S Liu; J Park; C Ellis; S Ganguly; S Konchar; J Cluderay; R Leslie; S Wilson; H M Sarau Journal: Nature Date: 1999-07-15 Impact factor: 49.962
Authors: Y Ravussin; R Gutman; S Diano; M Shanabrough; E Borok; B Sarman; A Lehmann; C A LeDuc; M Rosenbaum; T L Horvath; R L Leibel Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-03-16 Impact factor: 3.619
Authors: Timothy J Kowalski; Brian D Spar; Blair Weig; Constance Farley; John Cook; Lorraine Ghibaudi; Steve Fried; Kim O'Neill; Robert A Del Vecchio; Mark McBriar; Henry Guzik; John Clader; Brian E Hawes; Joyce Hwa Journal: Eur J Pharmacol Date: 2006-03-13 Impact factor: 4.432
Authors: Beth Borowsky; Margaret M Durkin; Kristine Ogozalek; Mohammad R Marzabadi; John DeLeon; Bharat Lagu; Rainer Heurich; Harvey Lichtblau; Zoya Shaposhnik; Irena Daniewska; Thomas P Blackburn; Theresa A Branchek; Christophe Gerald; Pierre J Vaysse; Carlos Forray Journal: Nat Med Date: 2002-07-15 Impact factor: 53.440
Authors: Kristoffer Rosenstand; Kenneth Andersen; Rasmus Terp; Peter Gennemark; Ditte Gry Ellman; Anna Reznichenko; Kate Lykke Lambertsen; Paul M Vanhoutte; Pernille B L Hansen; Per Svenningsen Journal: J Physiol Biochem Date: 2020-02-03 Impact factor: 4.158
Authors: Omar Al-Massadi; Carlos Dieguez; Marc Schneeberger; Miguel López; Markus Schwaninger; Vincent Prevot; Ruben Nogueiras Journal: Nat Rev Endocrinol Date: 2021-10-04 Impact factor: 47.564
Authors: P Gennemark; M Trägårdh; D Lindén; K Ploj; A Johansson; A Turnbull; B Carlsson; M Antonsson Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-05-27
Authors: Staci E Engle; Patrick J Antonellis; Logan S Whitehouse; Ruchi Bansal; Michelle R Emond; James D Jontes; Robert A Kesterson; Kirk Mykytyn; Nicolas F Berbari Journal: Genesis Date: 2018-08 Impact factor: 2.487